Cargando…

Incidence of postpartum depression after treatment of postpartum anaemia with intravenous ferric carboxymaltose, intravenous ferric derisomaltose or oral ferrous sulphate: A randomized clinical trial

OBJECTIVES: This study aimed to explore whether the type of iron preparation used to treat postpartum anaemia affects the incidence of postpartum depression and whether the risk of postpartum depression is higher in postpartum patients with anaemia who were adequately treated compared to the general...

Descripción completa

Detalles Bibliográficos
Autores principales: Bombač Tavčar, Lea, Hrobat, Hana, Gornik, Lea, Globevnik Velikonja, Vislava, Lučovnik, Miha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10598402/
https://www.ncbi.nlm.nih.gov/pubmed/37885813
http://dx.doi.org/10.1016/j.eurox.2023.100247
_version_ 1785125546659676160
author Bombač Tavčar, Lea
Hrobat, Hana
Gornik, Lea
Globevnik Velikonja, Vislava
Lučovnik, Miha
author_facet Bombač Tavčar, Lea
Hrobat, Hana
Gornik, Lea
Globevnik Velikonja, Vislava
Lučovnik, Miha
author_sort Bombač Tavčar, Lea
collection PubMed
description OBJECTIVES: This study aimed to explore whether the type of iron preparation used to treat postpartum anaemia affects the incidence of postpartum depression and whether the risk of postpartum depression is higher in postpartum patients with anaemia who were adequately treated compared to the general postpartum population. STUDY DESIGN: Single-center, open-label, randomized trial. Women were allocated to receive intravenous ferric carboxymaltose, intravenous ferric derisomaltose or oral ferrous sulphate. Intravenous iron was given in one or two doses, while ferrous sulphate as two 80 mg tablets once daily. Primary outcome was postpartum depression measured by Edinburgh Postnatal Depression Scale (EPDS) six weeks postpartum. Haematological parameters were analyzed as secondary outcomes. Kruskal-Wallis test was used for group comparison (p < 0.05 significant). The chi-square test was applied to compare categorical variables as well as the group of all subjects treated for anaemia in the study with the historical data for the Slovenian postpartum population. RESULTS: Three-hundred women with postpartum anemia (hemoglobin < 100 g/L within 48-hours postpartum) were included between September 2020 and March 2022 in tertiary perinatal center. Most characteristics were similar across groups. EPDS score at six weeks postpartum did not differ between groups. The treatment modality of postpartum anaemia did not have a statistically significant effect on the EPDS score six weeks after treatment (p = 0.10), nor did it have a statistically significant effect on the difference in EPDS scores before and after treatment (p = 0.68). The proportions of participants who scored 10 or more points on the EPDS scores at six weeks postpartum were not statistically different between the groups (p = 0.79). The proportion of participants with an EPDS score of 10 or more at six weeks postpartum in the total study population did not differ significantly from previously reported proportion of postpartum women with EPDS score of 10 or more in the general population (12 % vs. 21 %; p < 0.001). CONCLUSIONS: Maternal depression at 6 weeks postpartum did not differ in women treated for postpartum anemia with intravenous ferric carboxymaltose, intravenous ferric derisomaltose or oral ferrous sulphate. Participants with postpartum anaemia who are adequately treated with either oral or intravenous iron preparations are not at a higher risk of postpartum depression than the general population at six weeks postpartum.
format Online
Article
Text
id pubmed-10598402
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-105984022023-10-26 Incidence of postpartum depression after treatment of postpartum anaemia with intravenous ferric carboxymaltose, intravenous ferric derisomaltose or oral ferrous sulphate: A randomized clinical trial Bombač Tavčar, Lea Hrobat, Hana Gornik, Lea Globevnik Velikonja, Vislava Lučovnik, Miha Eur J Obstet Gynecol Reprod Biol X Obstetrics and Maternal Fetal Medicine OBJECTIVES: This study aimed to explore whether the type of iron preparation used to treat postpartum anaemia affects the incidence of postpartum depression and whether the risk of postpartum depression is higher in postpartum patients with anaemia who were adequately treated compared to the general postpartum population. STUDY DESIGN: Single-center, open-label, randomized trial. Women were allocated to receive intravenous ferric carboxymaltose, intravenous ferric derisomaltose or oral ferrous sulphate. Intravenous iron was given in one or two doses, while ferrous sulphate as two 80 mg tablets once daily. Primary outcome was postpartum depression measured by Edinburgh Postnatal Depression Scale (EPDS) six weeks postpartum. Haematological parameters were analyzed as secondary outcomes. Kruskal-Wallis test was used for group comparison (p < 0.05 significant). The chi-square test was applied to compare categorical variables as well as the group of all subjects treated for anaemia in the study with the historical data for the Slovenian postpartum population. RESULTS: Three-hundred women with postpartum anemia (hemoglobin < 100 g/L within 48-hours postpartum) were included between September 2020 and March 2022 in tertiary perinatal center. Most characteristics were similar across groups. EPDS score at six weeks postpartum did not differ between groups. The treatment modality of postpartum anaemia did not have a statistically significant effect on the EPDS score six weeks after treatment (p = 0.10), nor did it have a statistically significant effect on the difference in EPDS scores before and after treatment (p = 0.68). The proportions of participants who scored 10 or more points on the EPDS scores at six weeks postpartum were not statistically different between the groups (p = 0.79). The proportion of participants with an EPDS score of 10 or more at six weeks postpartum in the total study population did not differ significantly from previously reported proportion of postpartum women with EPDS score of 10 or more in the general population (12 % vs. 21 %; p < 0.001). CONCLUSIONS: Maternal depression at 6 weeks postpartum did not differ in women treated for postpartum anemia with intravenous ferric carboxymaltose, intravenous ferric derisomaltose or oral ferrous sulphate. Participants with postpartum anaemia who are adequately treated with either oral or intravenous iron preparations are not at a higher risk of postpartum depression than the general population at six weeks postpartum. Elsevier 2023-10-12 /pmc/articles/PMC10598402/ /pubmed/37885813 http://dx.doi.org/10.1016/j.eurox.2023.100247 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Obstetrics and Maternal Fetal Medicine
Bombač Tavčar, Lea
Hrobat, Hana
Gornik, Lea
Globevnik Velikonja, Vislava
Lučovnik, Miha
Incidence of postpartum depression after treatment of postpartum anaemia with intravenous ferric carboxymaltose, intravenous ferric derisomaltose or oral ferrous sulphate: A randomized clinical trial
title Incidence of postpartum depression after treatment of postpartum anaemia with intravenous ferric carboxymaltose, intravenous ferric derisomaltose or oral ferrous sulphate: A randomized clinical trial
title_full Incidence of postpartum depression after treatment of postpartum anaemia with intravenous ferric carboxymaltose, intravenous ferric derisomaltose or oral ferrous sulphate: A randomized clinical trial
title_fullStr Incidence of postpartum depression after treatment of postpartum anaemia with intravenous ferric carboxymaltose, intravenous ferric derisomaltose or oral ferrous sulphate: A randomized clinical trial
title_full_unstemmed Incidence of postpartum depression after treatment of postpartum anaemia with intravenous ferric carboxymaltose, intravenous ferric derisomaltose or oral ferrous sulphate: A randomized clinical trial
title_short Incidence of postpartum depression after treatment of postpartum anaemia with intravenous ferric carboxymaltose, intravenous ferric derisomaltose or oral ferrous sulphate: A randomized clinical trial
title_sort incidence of postpartum depression after treatment of postpartum anaemia with intravenous ferric carboxymaltose, intravenous ferric derisomaltose or oral ferrous sulphate: a randomized clinical trial
topic Obstetrics and Maternal Fetal Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10598402/
https://www.ncbi.nlm.nih.gov/pubmed/37885813
http://dx.doi.org/10.1016/j.eurox.2023.100247
work_keys_str_mv AT bombactavcarlea incidenceofpostpartumdepressionaftertreatmentofpostpartumanaemiawithintravenousferriccarboxymaltoseintravenousferricderisomaltoseororalferroussulphatearandomizedclinicaltrial
AT hrobathana incidenceofpostpartumdepressionaftertreatmentofpostpartumanaemiawithintravenousferriccarboxymaltoseintravenousferricderisomaltoseororalferroussulphatearandomizedclinicaltrial
AT gorniklea incidenceofpostpartumdepressionaftertreatmentofpostpartumanaemiawithintravenousferriccarboxymaltoseintravenousferricderisomaltoseororalferroussulphatearandomizedclinicaltrial
AT globevnikvelikonjavislava incidenceofpostpartumdepressionaftertreatmentofpostpartumanaemiawithintravenousferriccarboxymaltoseintravenousferricderisomaltoseororalferroussulphatearandomizedclinicaltrial
AT lucovnikmiha incidenceofpostpartumdepressionaftertreatmentofpostpartumanaemiawithintravenousferriccarboxymaltoseintravenousferricderisomaltoseororalferroussulphatearandomizedclinicaltrial